Format

Send to

Choose Destination
Anticancer Res. 2016 Dec;36(12):6381-6388.

Dynamin 2 Inhibitors as Novel Therapeutic Agents Against Cervical Cancer Cells.

Author information

1
Division of Gynecologic Oncology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
2
Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
3
School of Life Sciences, Gwangju Institute of Science and Technology, Gwangju, Republic of Korea.
4
Department of Pathology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
5
Department of Pathology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea garden.lee@samsung.com.

Abstract

AIM:

We investigated the feasibility of dynamin 2 as a potential treatment target in cervical cancer cells.

MATERIALS AND METHODS:

We performed tissue microarray for dynamin 2 expression in 208 patients with early cervical cancer and in vitro in HeLa cells with dynamin 2 inhibitors MiTMAB, OcTMAB, Dynasore, and DD-6.

RESULTS:

Tumor size greater than 2 cm or tumor invasion of more than half of the entire cervix was associated with expression of dynamin 2 compared to no expression (p=0.013, and p=0.045, respectively). All dynamin 2 inhibitors significantly reduced proliferation, increased apoptotic activity, and reduced matrix metallopeptidase 9 expression in HeLa cells. Dynasore and DD-6 reduced migration of HeLa cells on laminin 1-coated plates and DD-6 most strongly reduced migration performance on fibronectin-coated plates.

CONCLUSION:

Targeting dynamin 2 may be a promising new approach for the treatment of cervical cancer.

KEYWORDS:

Cervical cancer; DD-6; Dynasore; MiTMAB; OcTMAB; dynamin 2

PMID:
27919959
DOI:
10.21873/anticanres.11235
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center